Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of the firm’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $11.38, for a total value of $24,501.14. Following the completion of the transaction, the insider now owns 195,840 shares of the company’s stock, valued at approximately $2,228,659.20. This represents a 1.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded down $0.48 during midday trading on Thursday, reaching $11.88. The stock had a trading volume of 1,326,717 shares, compared to its average volume of 2,173,789. The stock’s 50-day simple moving average is $15.10 and its 200 day simple moving average is $25.73. Dyne Therapeutics, Inc. has a twelve month low of $11.18 and a twelve month high of $47.45. The stock has a market capitalization of $1.34 billion, a PE ratio of -3.34 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Scotiabank began coverage on Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research report on Wednesday. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.85.

Institutional Trading of Dyne Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics during the 4th quarter worth approximately $50,000. Neo Ivy Capital Management acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Dyne Therapeutics by 6.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock worth $3,378,000 after acquiring an additional 9,029 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth about $2,804,000. Finally, Two Sigma Advisers LP boosted its holdings in Dyne Therapeutics by 25.4% in the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock valued at $1,793,000 after purchasing an additional 15,400 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.